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ABSTRACT: Paper-based lateral ﬂow immunoassays
(LFIAs) are one of the most widely used point-of-care
(PoC) devices; however, their application in early disease
diagnostics is often limited due to insuﬃcient sensitivity for
the requisite sample sizes and the short time frames of PoC
testing. To address this, we developed a serum-stable,
nanoparticle catalyst-labeled LFIA with a sensitivity
surpassing that of both current commercial and published
sensitivities for paper-based detection of p24, one of the
earliest and most conserved biomarkers of HIV. We report
the synthesis and characterization of porous platinum
core−shell nanocatalysts (PtNCs), which show high catalytic activity when exposed to complex human blood serum
samples. We explored the application of antibody-functionalized PtNCs with strategically and orthogonally modiﬁed
nanobodies with high aﬃnity and speciﬁcity toward p24 and established the key larger nanoparticle size regimes needed for
eﬃcient ampliﬁcation and performance in LFIA. Harnessing the catalytic ampliﬁcation of PtNCs enabled naked-eye
detection of p24 spiked into sera in the low femtomolar range (ca. 0.8 pg·mL−1) and the detection of acute-phase HIV in
clinical human plasma samples in under 20 min. This provides a versatile absorbance-based and rapid LFIA with sensitivity
capable of signiﬁcantly reducing the HIV acute phase detection window. This diagnostic may be readily adapted for
detection of other biomolecules as an ultrasensitive screening tool for infectious and noncommunicable diseases and can be
capitalized upon in PoC settings for early disease detection.
KEYWORDS: lateral ﬂow immunoassay, porous platinum core−shell nanoparticles, broad dynamic range, enzyme mimic, nanobodies,
biorthogonal chemistry, point-of-care, HIV detection
The emergence of infectious diseases is one of thegreatest threats to human health. The recent outbreaksof Zika and Ebola viruses and the ongoing HIV
pandemic continue to highlight the need for diagnostic tools
that are aﬀordable, sensitive, simple, and able to rapidly detect
pathogens under challenging circumstances. These demands
have led to the uptake of paper-based lateral ﬂow immuno-
assays (LFIAs) as the most prominent rapid point-of-care
(PoC) diagnostic tests. Although meeting many of these
criteria, their sensitivity generally falls short of other benchtop
protein and nucleic acid detection methods.1 The continuing
hurdle of developing PoC diagnostics is that compromises must
be made between sensitivity, simplicity, speed, and cost. A great
challenge is the development of diagnostics for use in resource-
limited settings that require exceptional performance in all
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these categories but also resilience toward a lack of cold-chain
support.
Sensitive diagnostic platforms often include signal or target
ampliﬁcation mechanisms, such as polymerase-chain reaction
(PCR) and isothermal nucleic acid ampliﬁcation for detection
of nucleic acids or enzyme-catalyzed signal ampliﬁcation and
immuno-PCR for detection of protein targets.2,3 However,
these techniques are relatively resource demanding, requiring
technical expertise to run and interpret (e.g., puriﬁcation steps)
and utilize equipment that is often incompatible with use in
resource-limited settings where unreliable power supplies and
maintenance challenges restrict their use.4,5 Due to their high
catalytic eﬃciency and extraordinary stability in harsh environ-
ments, such as high temperature and extreme pH, mixed noble-
metal catalytic nanoparticles have emerged as promising
materials for signal ampliﬁcation in colorimetric immuno-
assays.6−11 We show here that incorporating inorganic
nanoparticle catalysts in lateral-ﬂow testing formats, through
an investigation of their size and porosity, provides a pathway
to signiﬁcantly improve the sensitivity of simple to read,
absorbance-based LFIAs. This has resulted in a simple and cost-
eﬀective paper based diagnostic test with a level of performance
far in advance of current standards for LFIA.
Here, we integrate peroxidase-mimicking porous platinum
core−shell nanocatalysts (PtNCs) into a LFIA for sensitive
detection of p24, the viral capsid protein of HIV. Acute HIV
infection poses a unique challenge in diagnosis as it
encompasses a period from initial infection to complete
seroconversion (the period over which patient antibodies
against proteins of HIV develop). During this window period,
there is a lack of detectable circulating biomarkers, with
antibodies appearing ca. 28 days after infection.12,13 HIV p24 is
the earliest protein biomarker post infection, and a test capable
of detecting p24 earlier would be transformative in key target
settings, such as the diagnosis of infants whose mothers are
known to be HIV positive, where antibody tests are unreliable,
and also to ensure early intervention with antiretroviral
therapies where they have the potential to be most
beneﬁcial.14−17 However, clinically relevant ranges of p24
during acute infection are far below the detectable limit of the
leading ﬁeld-ready colorimetric LFIA tests (ca. 10−15 pg·
mL−1),18−20 which are limited by the absorbance of the colored
label and the aﬃnities of the antibody recognition compo-
nents.21
Through the design and optimization of a nanocatalyst
ampliﬁcation platform, high-aﬃnity and orthogonally designed
binding components, and lateral ﬂow architecture, we
demonstrate a high level of sensitivity and broad dynamic
range previously unattainable in LFIA formats. The catalytic
ampliﬁcation process developed herein allows the test, in spiked
Figure 1. (a) Scheme showing ampliﬁed LFIA, where functionalized Pt nanocatalysts (PtNCs) and biotinylated nanobody fragments are mixed
with a plasma or serum sample. In the presence of a target, PtNCs become biotinylated through complexation with the target, and rapid high
aﬃnity biotin−streptavidin binding enables a [target] dependent deposition of PtNC at the test line. PtNCs bound at the test line catalyze the
oxidation of CN/DAB (4-chloro-1-naphthol/3,3′-diaminobenzidine, tetrahydrochloride) substrate in the presence of hydrogen peroxide
producing an insoluble black product which is clearly visible with the naked eye. (b) Scheme for site-selective chemical modiﬁcation of a
nanobody with an exposed cysteine mutation (red), where lysine residues are highlighted in orange on the structural model (left), and cartoon
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serum, to surpass the published sensitivity of the leading
commercial rapid tests for p24 (Alere Determine HIV-1/2 Ag/
Ab Combo and Alere HIV Combo, for example) by a factor of
up to 20. Here, we show detection of low femtomolar
concentrations of p24 in spiked serum (ca. 32.5 fM), and
naked-eye detection of acute stage HIV in clinical plasma
samples in under 20 min.
RESULTS AND DISCUSSION
The LFIA is used to quickly establish whether a target analyte is
present in a complex sample (blood, plasma, sera, etc.) using a
simple colorimetric readout. The core process in a LFIA
initiates when a detection label (typically an intensely colored
nanoparticle) is hydrated by the sample, drawn along the paper
membrane by capillary action and bound, via a target analyte, to
a region of the strip called the test line. To achieve this, both
the nanoparticles and the test line must be decorated with
aﬃnity ligands (typically antibodies) capable of binding discrete
regions of the target analyte. In order to achieve a high level of
sensitivity in a LFIA format, the components must exhibit fast
binding reaction kinetics toward the solid-phase to ensure that
the particle labels can bind to the test line within the short time
window during which the sample is ﬂowing past. The use of a
high aﬃnity binding system like biotin−streptavidin (KD ca.
10−15 M) for the test line binding capture step is essential for
moving toward the goal where all target antigens are labeled
with a nanoparticle at the test line.22 The advantage of this
architecture means that the antibody-binding complex forms in
solution such that the biotin−streptavidin interaction is the
rapid binding event which immobilizes the complex at the test
line. This circumvents the often poor performance of
conventional antibody capture, as the biotin−streptavidin
binding aﬃnity is over 4 orders of magnitude higher than a
conventional antibody−antigen interaction.23
ur PtNC ampliﬁed LFIA takes advantage of the simple, low
cost LFIA platform but incorporates a strong ampliﬁcation
mechanism through the catalytic activity of the nanoparticle
itself to increase the signal intensity through local deposition of
dyes at the test line. The schematic in Figure 1a highlights the
essential components and conﬁguration of the PtNC ampliﬁed
LFIA. During the assay, a plasma (or serum) sample is
introduced into a vessel containing both lyophilized antibody
modiﬁed PtNCs and agile, orthogonally biotinylated camelid
antibody fragments (nanobody-biotin) capable of binding to
discrete epitope regions of the p24 capsid protein. Next, a
lateral ﬂow strip, composed of a nitrocellulose reaction
membrane and an absorbent pad, is used to draw the solution
up the strip toward a streptavidin bearing test line by capillary
action. Where present, p24 in the sample can then be
sandwiched between the antibody−PtNC conjugate and a
biotinylated antibody fragment, forming a biotinylated complex
that is captured at the streptavidin coated test line. At high
target concentrations (100−10000 pg·mL−1 p24), a clear black
line is visible with the naked eye due to the intrinsic absorbance
of the particles bound at the test line, indicating a positive test
result. Lower concentrations of the target are visualized by
taking advantage of the catalytic ampliﬁcation of the PtNCs
that act to disproportionate H2O2, enabling the oxidation of a
chromogenic substrate.24−27 After running the plasma sample
through, followed by a chase buﬀer, the test line is exposed to a
mixture of hydrogen peroxide and a chromogenic substrate.
Any PtNC captured on the test line will oxidize the substrate,
generating an insoluble colored product. This ampliﬁcation step
increases the window of sensitivity and lowers the detection
limit by 2 orders of magnitude. Because of the unambiguous
colored product deposited at the test line, the assay result can
be easily read by eye or captured by a mobile phone camera for
analysis, with the potential for semiquantitative result readout
with a pre- and postampliﬁcation signal regime.
Figure 1b outlines the site-selective modiﬁcation strategy
used to prepare robust antibody fragments with oriented biotin
presentation in the assay. Speciﬁcally, we have integrated a
thermally robust and high-aﬃnity nanobody component into
the nanocatalyst-labeled LFIA. Nanobodies are single domain
antibody fragments that contain a complete antigen-binding site
but are one tenth the size of a conventional antibody. In
addition to their small size and stable conformation, they can be
eﬃciently mass produced in bacteria with site-selective
mutations that enable biorthogonal chemistry.28,29 Because of
the ease and control over nanobody modiﬁcation and
puriﬁcation, we chose to biotinylate a p24-binding nanobody
validated against a broad spectrum of HIV subtypes to facilitate
PtNC−analyte complex binding to the streptavidin test line.30
An anti-p24 nanobody containing a solvent-accessible
terminal cysteine residue was expressed to enable site-selective
biotinylation. The position of the cysteine residue, at the end of
a ﬂexible 6-mer HIS-tag linker, was chosen to maximize the
distance between the subsequent modiﬁcation and the paratope
of the nanobody (structural model in Figure 1b), thus
minimizing disruption.30 Site-selective biotinylation of the
cysteine residue was achieved through reaction with a biotin-
functionalized pyridazinedione (PD), the ﬁrst example of
nanobody modiﬁcation using PD chemistry (Supplementary
Methods and Characterization). Analysis of the nanobody
postmodiﬁcation using LCMS conﬁrmed addition of only a
single molecule of biotin, evidencing no undesirable oﬀ-target
conjugation. Pyridazinediones have a proven track record in
antibody modiﬁcation, and hold many advantages over other
cysteine-selective reagents such as maleimides and haloaceta-
mides, which have been shown to react with lysine residues
andw often display poor long-term stability.31−35 Through this
approach, we have speciﬁcally engineered the nanobody to
present biotin away from the p24 binding region, enabling
oriented presentation in our assay.
We examined the binding kinetics of the modiﬁed and
unmodiﬁed nanobodies with p24 and found that the site-
selective modiﬁcation had no signiﬁcant impact on the
dissociation constant, conﬁrming that the modiﬁcation does
not interfere with the antigen binding region (Supplementary
Table 1). The site-selectively biotinylated nanobody circum-
vents the nonspeciﬁc modiﬁcation of the nanobody paratope,
which is rich with lysine residues (highlighted in orange in
Figure 1b), where standard carbodiimide cross-linker mod-
iﬁcation strategies will risk interfering with the binding site and
thus knock out activity. The site-selective biotinylation of the
cysteine presenting nanobody preserves epitope recognition
and ensures eﬃcient use of the p24 available in the sample. We
selected a monoclonal antibody (anti-HIV-1/2, Capricorn
products), which is a p24 binding pair with the nanobody−
biotin, to physically adsorb onto the nanocatalysts.30 This
coupling of orthogonally modiﬁed nanobody and physisorbed
whole IgG antibody enabled the rapid engineering of a PtNC
ampliﬁed assay. Nanobody mutation, expression, and orthog-
onal modiﬁcation can be readily achieved within several days
where the preparation of the appropriate PtNC catalysts can be
performed simultaneously for use on a standard, commercially
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available streptavidin lateral ﬂow membrane (Supplementary
Figure 1).
Figure 1c highlights the broad dynamic range of PtNC
ampliﬁed LFIA, which spans over 4 orders of magnitude. This
dual sensitivity regime is enabled by the inherent coloration of
the PtNC (for detection of 100−10000 pg·mL−1 analyte) and
their ability to catalytically generate a colored product to
decorate the test line, accessing a second regime from 100 to
less than 1 pg·mL−1 analyte. This is ca. 2 orders of magnitude
broader dynamic range than standard colorimetric ELISAs or
fourth generation LFIAs, which are limited to either
postcatalysis or to the coloration of a particle label,
respectively.36
In order to produce PtNCs with high catalytic activity and
eﬀective antibody modiﬁcation, their synthesis required careful
optimization. At the early stages of production, the particles are
capped with polyvinylpyrrolidone (PVP) to ensure colloidal
stability (Supplementary Figure 2) and to reduce the extent of
fouling that occurs upon exposure to complex media during
LFIA. The molecular weight of PVP used during the particle
synthesis played an important role in dictating the catalytic
activity of the PtNCs (before antibody modiﬁcation) as
highlighted by their ability to oxidize tetramethylbenzidine
(TMB) in Figure 2a, with 10 kDa PVP-capped particles
performing optimally. A key performance requirement of the
antibody-capped PtNCs is that they can retain their catalytic
activity following exposure to complex environments such as
Figure 2. (a) Scheme showing synthesis of Au−Pt core−shell structure (PtNC), where 15 nm gold nanoparticles are used as seeds for
subsequent platinum overgrowth in the presence of polyvinylpyrrolidone (PVP) as a stabilizer and L-ascorbic acid as a reducing agent.
Inﬂuence of PVP molecular weight on PtNC catalytic activity, measured by the absorbance at 652 nm corresponding to the oxidation of TMB
by H2O2 (n = 3). In the absence of PVP, signiﬁcant aggregation occurred. (b) Catalytic activity of PtNCs incubated in serological and protein-
rich environments up to 24 h (n = 6). (c) Transmission electron micrographs of PtNCs synthesized with varying AuNP seed concentrations to
control size: (i) 5 nM seeds and (ii) 0.3 nM seeds. (iii) High-resolution TEM image of an individual PtNC formed from 0.3 nM seed
concentration. Inset shows the lattice fringes corresponding to platinum (111) and (200). (iv) Selected area electron diﬀraction (SAED)
pattern taken from a single PtNC (ca. 120 nm) with diﬀraction spots consistent with polycrystalline platinum with an FCC lattice. (d)
Number distribution of the hydrodynamic diameter of PtNCs formed by varying [Au]:[Pt] measured by dynamic light scattering. Batches
were synthesized in the presence of diﬀerent gold nanoparticle seed concentrations: A, 5 nM; B, 1.2 nM; C, 0.6 nM; D, 0.3 nM; E, 0.15 nM; F,
0.08 nM; G, 75 pM ca. 120 nm PtNCs as seeds; H, 40 pM ca. 120 nm PtNCs as seeds. (e) Intensity of test line for antibody modiﬁed PtNCs
(150 pM) varying in size from ca. 50 to 280 nm (mean number distribution by DLS) for detection of 100 pg·mL−1 p24 in FBS with 5 min
development in CN/DAB and H2O2. All data are averaged from ≥3 independent measurements where error bars represent the standard
deviation from the mean.
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patient serum, which contains ca. 7 wt % protein. Indeed,
PtNCs when prepared in this manner with 10 kDa PVP and
antibody modiﬁcation were found to retain a signiﬁcant amount
of the initial particle activity (ca. 75%) over a period of 24 h
(Figure 2b), far in excess of the exposure time expected during
a serological measurement. Although protein adsorption to the
PtNCs can reduce the catalytic activity of the particles, it has
the beneﬁt of making their modiﬁcation with antibodies simple,
where mixing the PtNCs with antibodies in the correct
stoichiometry and at an appropriate pH yields PtNCs with
eﬃciently conjugated antibodies (Supplementary Figure 3).
TEM images in Figure 2c and Supplementary Figure 4 show
the precise control over PtNC size and monodispersity possible
using the seeded synthesis. PtNCs could be produced with
porous, polycrystalline platinum shells.38,39 We have observed
that there is a signiﬁcant contribution to the PtNC catalytic
activity that arises from the internal catalytic surface area of the
particles as shown by assessing the role of gold core size for 15
and 40 nm cores (Supplementary Figure 5). This additional
surface area is accessible through nanometer-scale pores (ca. 1−
2 nm by TEM image analysis) within the platinum shell. This
likely renders the pores inaccessible to larger molecules (e.g.,
antibodies and serum proteins), but accessible to smaller
molecules such as H2O2, making them well suited for use in
catalytic ampliﬁcation processes following exposure to protein-
rich serum environments.
Selecting the smaller 15 nm gold nanoparticles as seeds,
PtNCs were produced with diameters up to approximately 280
nm by modulating the concentration of gold seeds used for
subsequent overgrowth (Figure 2d). Particles larger than ca.
150 nm were produced via a layer-by-layer deposition of
platinum on as-synthesized ca. 120 nm PtNCs. High-angle
annular dark-ﬁeld STEM (HAADF-STEM) images of PtNCs of
varying size with corresponding energy dispersive X-ray point
spectra (EDS) conﬁrm core−shell structure, with Au core and
Pt conﬁned to the external porous shell (Supplementary Figure
6 and 7). Thanks to the well-deﬁned concentration of
nucleation points for overgrowth with platinum, the poly-
dispersity as measured by dynamic light scattering was
maintained at a low level (0.01 < PDI < 0.1) ensuring
reproducibility in their synthesis (Supplementary Figure 8).
The ﬁne size control of this seeded synthesis allows for control
over subsequent antibody modiﬁcation.
PtNCs provide an ideal platform for assessing the role of
catalytic particle size on sensitivity in LFIA by virtue of their
core−shell conﬁguration and their high porosity and the
resulting large surface area for catalysis that is retained
independent of the particle size. The nanometer-scale rough-
ness and morphology of the particles produced during this
seeded synthesis appeared unchanged with increasing size
(Supplementary Figures 4 and 6). The size of the nanocatalyst
has a distinct eﬀect on the test line signal intensity obtained for
PtNC sizes up to ca. 280 nm when employed in the LFIA.
Larger particles with increased surface area for catalytic
reactions would be expected to generate a higher signal in
LFIA format, and indeed, up to a point, this was observed
experimentally. PtNC sizes ranging 50 to 280 nm were
synthesized and modiﬁed with an optimal surface density of
antibody (Supplementary Figure 3). Keeping the PtNC
concentrations constant (150 pM), the diﬀerent sized PtNCs
were used as catalytic labels in the LFIA format for serum
samples spiked with 100 pg·mL−1 p24 and the biotinylated
nanobody. The resulting variation in signal intensity as a
function of particle size is shown in Figure 2e. Larger particles
were found to result in increased signal intensity reﬂecting the
increased surface area available for catalytic reactions. However,
we observed that this eﬀect was most prominent approaching a
threshold in the region of 150 nm, above which a reduced
performance was observed. This reduced signal intensity for
larger particles may be due to a reduction in diﬀusivity and a
concomitant decrease in internal porosity (and therefore
catalytic activity), resulting from the layer-by-layer synthesis
(Supplementary Figure 7). An optimal performance regime was
exhibited by PtNCs in the 120−200 nm diameter range, so due
to their facile one-step synthesis, low nonspeciﬁc binding, and
minimizing the need to use excessive platinum, 120 nm PtNCs
were used for further experiments.
Looking toward the challenges of translation, we investigated
both the reproducibility and stability of the test reagents. Figure
3a shows the test line intensity produced by ﬁve independently
synthesized batches of ca. 120 nm PtNCs for detection of 50
pg·mL−1 p24 spiked sera (Supplementary Figure 8). The red
line indicates the average test line intensity across batches. The
coeﬃcient of variation between ﬁve independently synthesized
and antibody modiﬁed batches was 2.4%, indicating that PtNC
ampliﬁed LFIA is reproducible through the synthesis, antibody
Figure 3. (a) Intensity of test line for ﬁve independently
synthesized batches of PtNCs (ca. 120 nm) for detection of 50
pg·mL−1 p24 in FBS with 5 min development in CN/DAB and
H2O2. Red line indicates average test line intensity for triplicate
measurements across all batches. Coeﬃcient of variation (n = 5)
was 2.4%. (b) Intensity of test line (for detection of 500 pg·mL−1
p24-spiked plasma) against days of test component aging at 44 °C
or room temperature (RT). For the aging experiment, nanobody−
biotin and either PtNC or HRP−antibody conjugates were
lyophilized in appropriate buﬀers and incubated at speciﬁed
temperature. At aging time points, spiked plasma was added to
the vessel of freeze-dried components and ﬂowed up the LFIA test
strip followed by catalytic ampliﬁcation.
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conjugation, and assay running steps. This suggests that our
nanocatalyst platform holds great promise for reliable clinical
sample detection.
Stability is a key aspect of PoC devices where the
performance of both the detection labels and the antibody
components must be independent of the storage conditions the
test might be exposed to. Many assays require controlled
temperature storage conditions, which imposes cost on the
supply chain and may prevent use in high temperature regions,
thus limiting the test’s use in the developing world. Enzymes
and antibody reagents are typically the most susceptible
components to long-term storage, although with appropriate
drying conditions and matrices, long-term dried storage is
possible.37 Accelerated aging studies, shown in Figure 3b, were
carried out on lyophilized reagents−comparing the stability of
peroxidase-mimicking PtNC labels to their biological counter-
part horseradish peroxidase (HRP), the most common enzyme
used for catalytic ampliﬁcation in immunoassays. For aging
studies, nanobody−biotin and either antibody-conjugated HRP
or PtNC were lyophilized in buﬀer mixtures containing sucrose,
BSA, PVP, and Tween-20. After freeze-drying and aging at 44
°C or room temperature over a period of 6 weeks, p24 spiked
plasma was added to the dried samples and ﬂowed up the strip,
and the test line intensity was quantiﬁed after catalytic
ampliﬁcation. PtNC-ampliﬁed LFIA showed no notable change
in test line intensity over 6 weeks aging at room temperature,
and only minimal change in test line intensity when incubated
at 44 °C for 6 weeks (6-month room temperature aging
equivalent). An initial ca. 25% decrease in signal intensity was
observed after 3 days of incubation at 44 °C, after which no
additional signal was lost over a 42-day period. In contrast, anti-
HIV-1/2 antibody-functionalized HRP labels were found to
lose 90% of signal intensity after 2 weeks of room temperature
dry storage when run in LFIA (these samples did not withstand
elevated temperature aging conditions). The resilience of these
components is critical in determining the systems suitability for
PoC use, especially in resource-limited settings where cold-
chain transport is not guaranteed. In particular, this highlights
the beneﬁt of using robust inorganic catalytic nanoparticles in
the place of conventional enzymes where the catalytic
ampliﬁcation obtained using the porous PtNCs is highly
resilient to rapid aging. Conventional antibodies can be readily
physisorbed onto metallic nanoparticles and show signiﬁcant
thermal stability when lyophilized. We also observe excellent
long-term stability of the biorecognition components in our
ampliﬁed LFIA, where we employ a combination of a
conventional antibody and a biotinylated nanobody. However,
we note that nanobodies exhibit signiﬁcantly greater thermal
stability than conventional immunoglobulins (Supplementary
Figure 9) and we see great potential in pairing two nanobody
components in this system to further improve the thermal
stability for use in the most adverse conditions.38−42
The sensitivity of the nanocatalyst-labeled LFIA (employing
ca. 120 nm PtNC labels) before and after catalysis is
highlighted in Figure 4a with a plot of the signal intensity
and the concentration of p24 in spiked sera before and after
catalytic ampliﬁcation. Test line signal intensity was captured by
a mobile phone camera, a readily available tool for image
acquisition. Unlike enzyme-labeled immunoassays which
require catalysis for visualization, the PtNC-labeled LFIA
achieves two windows of sensitivity, pre- and postcatalysis,
taking advantage of both the absorbance of the particles and
their peroxidase-mimicking activity (Supplementary Figure 10).
This empowers the assay with a dual range diagnostic regime,
quantiﬁable by use of mobile phone-based detection and image
analysis. Our assay exhibits a linear dynamic range across over 4
Figure 4. (a) Test line intensity obtained by mobile phone camera
images for a dilution series of p24 spiked into sera before (black)
and after ampliﬁcation (red) in a mixture of CN/DAB and H2O2
for 5 min using ca. 120 nm PtNC labels. Error bars represent
standard deviation from three independent experiments. (b)
Illustration of the broad linear dynamic range across 4 orders of
magnitude from 10000 to 1 pg·mL−1 achieved with the present
method with nonlinear (log scale) regression least-squares ﬁt
(predevelopment: 0.62x + 1.7, R2 = 0.9813; postdevelopment:
0.61x + 3.0, R2 = 0.9853). (c) Clinical sample HIV seroconversion
panel results for a single donor showing the change in test line
intensity as a function of sample blood collection date covering the
seroconversion period. 50 μL of each clinical sample was added to a
vessel containing lyophilized test reagents and run up the LFIA
strip followed by catalytic ampliﬁcation. Red dotted line indicates
cutoﬀ (average test line intensity of 3 nonspiked blank plasma
samples plus three times standard deviation). Error bars represent
standard deviation from three independent experiments.
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orders of magnitude from 10000 to <1 pg·mL−1 protein target
(Figure 4b) through measurement pre- and post-ampliﬁcation.
This can enable a broader potential quantitative range of the
test if an image is taken before and after chromogen
ampliﬁcation. PtNC-ampliﬁed LFIA can enable the detection
of p24 in spiked sera down to a level of 0.8 pg·mL−1 (ca. 32.5
fM) in under 20 min, which is within the clinically relevant
range for [p24] during acute stage infection when the individual
is most infectious but also when early intervention with
antiretroviral therapies is most beneﬁcial.17
We evaluated the performance of the PtNC LFIA in clinical
human plasma samples using an HIV seroconversion panel
collected by ZeptoMetrix (Panel Donor No. 75062).
Longitudinal clinical samples from the same donor spanning
a one-month blood collection period encompassing serocon-
version were assessed. In a blinded experiment, PtNC ampliﬁed
LFIA could successfully detect positive antigen levels in
infected plasma from ZeptoMetrix panel samples 7 through
14 corresponding to increasing levels of antigen in the blood
during acute phase infection, followed by immune complex
formation (Figure 4c). Panel samples 13 and 14 correspond to
low levels of p24: 10.8 pg·mL−1 ∼ 211000 copies/mL HIV-1
RNA and 4.6 pg·mL−1 ∼ 46300 copies/mL, respectively
(veriﬁed by ZeptoMetrix HIV p24 antigen ELISA and Roche
Cobas Amplicor HIV-1 Monitor). A fourth-generation HIV
LFIA test incorporates an antibody detection line to ensure the
test can detect HIV infection across the seroconversion regime.
We envisage a similar approach with the PtNC-ampliﬁed LFIA
which would still beneﬁt from the increased dynamic range for
immune response monitoring but also exceptional levels of
sensitivity toward p24 at the early stages of infection.
CONCLUSIONS
Here we report one of the simplest and most sensitive
absorbance-based LFIA for protein detection to date,
demonstrate its utility in a clinically signiﬁcant range for p24
detection in spiked sera and plasma, and detection of acute
phase HIV infection in serial clinical samples. We achieve
sensitivity in a simple paper-based platform by pairing porous
catalytic inorganic nanoparticles and thermally robust antibody
fragments with easily modiﬁable functional groups for oriented
presentation of the solid phase recognition elements. Capital-
izing on the porous nature of the catalyst, we establish the
optimal size regime for catalytic nanoparticles as amplifying
labels in LFIA. We balance the high catalytic activity of the
noble metal PtNCs toward peroxide disproportionation with
the simultaneous tendency for biomolecules to adsorb and
block the reactive surface by careful tailoring of PVP coatings
and antibody conjugation. We demonstrate the utility of both
nanobody and nanocatalyst components in LFIA to move
toward a simple, robust, and highly amplifying system. The
result is a PtNC ampliﬁed LFIA that is easy to use with a
colorimetric output that can be read by the naked-eye or by
mobile phone camera. The applications for this rapid test with
broad dual dynamic range extend far beyond HIV diagnostics.
This sensitive platform can be readily adapted for detection of
other biomarkers across multiple stages of disease progression
and monitoring of therapeutic eﬃcacy. Our versatile and
modular platform incorporates highly eﬃcient inorganic
catalytic labels into existing LFIA technology, enhancing its
potential uptake into PoC diagnostics for the detection of any
protein target.
MATERIALS AND METHODS
Synthesis of Gold Nanoparticle Seeds. Gold nanoparticle seeds
with a diameter of ca. 15 nm were synthesized by sodium citrate
reduction of HAuCl4. In a typical synthesis, 10 mL of gold(III)
chloride trihydrate aqueous solution (20 mM, Sigma) was added to
180 mL of puriﬁed water under reﬂux at 100 °C. The temperature was
then reduced to 70 °C, and the reaction initiated by fast injection of 10
mL of trisodium citrate dihydrate (68 mM, BDH Chemicals) with
vigorous stirring and reﬂuxed for 5 min. The resulting ca. 15 nm gold
nanoparticle (AuNP) seeds were cooled to room temperature and
subsequently stored at 4 °C (Supplementary Figure 2). Seed
concentration was determined by TEM size analysis and initial gold
concentration.
Synthesis of Porous Platinum Core−Shell Nanoparticles
(PtNCs). 120 nm PtNCs were synthesized via reduction of
chloroplatinic acid hydrate on gold seeds adapted from Gao et al.9
In a typical synthesis, 31 μL (10 nM) of 15 nm Au seeds were mixed
with 969 μL of puriﬁed water (Milli-Q), followed by addition of 20 μL
of 20 wt % poly(vinylpyrrolidone) (PVP MW 10 kDa, Sigma). The
solution was vortexed brieﬂy and incubated for 5 min for the polymer
to coat and stabilize particles. L-Ascorbic acid (40 μL, 100 mg·mL−1,
Sigma) was then added to the mixture followed by 40 μL of
chloroplatinic acid hydrate (100 mM, Sigma), mixed, and immediately
incubated at 65 °C for 30 min until the color of the solution changed
from red to brown/black indicating successful deposition of platinum
(Supplementary Figure 2). PtNCs were then cooled to room
temperature in a water bath, and excess reagents were removed
through four sequential washing cycles at 1250 rcf for 12 min with
resuspension into puriﬁed water. PtNC size in the range of 50−120
nm was controlled by changing the volume of Au seed solution while
keeping the amount of PVP, ascorbic acid, and H2PtCl6 constant.
PtNCs larger than 120 nm (mean number distribution by DLS)
were synthesized via a stepwise layer-by-layer platinum reduction and
deposition approach. 120 nm PtNCs were used as seeds for
subsequent deposition of platinum layers iterating on the above
synthesis to achieve colloidally stable PtNCs up to ca. 280 nm.
Characterization of Nanoparticles. Dynamic light scattering
(DLS, Zeta Sizer Nanoseries, Malvern Instruments, Ltd.) was used to
characterize the hydrodynamic radius of nanoparticles. Absorption
measurements were recorded on a SpectraMax M5 multimode
microplate reader (Molecular Devices, Ltd.). For electron microscopy
characterization, samples were drop-casted onto carbon-coated copper
grids (Electron Microscopy Sciences), and TEM imaging was
performed using a JEOL 2100Plus or JEOL 2100F operating at 200
kV. High angle annular dark ﬁeld (HAADF) images were acquired in
scanning transmission electron microscopy (STEM) mode using a
camera length of 10−12 cm (HAADF5) on JEOL 2100F. The
microscope was equipped with Gatan Orius SC 1000 (2 × 4k) high-
angle annular dark ﬁeld detector, Gatan annular dark ﬁeld detector/
bright ﬁeld detector. Small camera length ensured that diﬀraction
contrast was excluded from the imaging and contrast was related to the
atomic number (Z) or density of the particles. Corresponding
elemental compositional mapping of PtNCs was determined by
energy-dispersive X-ray spectroscopy (EDS) in STEM mode.
Preparation of PtNC−antibody Conjugates. In a typical
conjugation, 200 μL of 120 nm PtNC (300 pM) was mixed with 20
μL of HEPES buﬀer (pH 6, 0.1 M) followed by addition of 2 μL of a
23 μM solution of monoclonal anti-HIV-1/2, puriﬁed (Capricorn
Products, HIV-018-48303); optimization of [Ab]:[PtNC] is outlined
in Supplementary Figure 3. The mixture was incubated for 3.5 h under
shaking (800 rpm) at 20 °C for antibody physisorption. Modiﬁed
particles were subsequently blocked by addition of 200 μL of blocking
solution: 2 wt % β-casein from bovine milk (Sigma) in PBS for 1.5 h
under shaking (800 rpm) at 20 °C. Excess reagents were removed
through three wash steps in assay running buﬀer (0.2 wt % β-casein,
0.2 wt % Tween20 [Sigma] in 50 mM phosphate buﬀer pH 7.2).
Particles were ultimately resuspended in particle storage buﬀer (10 wt
% sucrose [Sigma], 1 wt % bovine serum albumin [BSA, Sigma], 1 wt
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% PVP 10 kDa, 0.1 wt % beta-casein, 0.1 wt % Tween20 in 50 mM
phosphate buﬀer pH 7.2).
Horseradish peroxidase was also modiﬁed with anti-HIV-1/2
antibody following Lightning-Link Horseradish Peroxidase kit (Innova
Biosciences) with no deviation from the manufacturer’s protocol.
Evaluation of Peroxidase-like Activity. All assays were carried
out at room temperature in a 96-well plate (Corning UK). For stability
and activity of PtNCs in complex environments, 10 μL of PtNCs or
antibody modiﬁed PtNCs (300 pM) were mixed with 90 μL of either
deionized water, 2 wt % β-casein in PBS, fetal bovine serum (FBS,
Sigma), or human plasma pool (Lee Biosciences) for up to 24 h at
room temperature. PtNCs were further diluted in puriﬁed water to 5
pM for catalytic activity test. For activity tests, 10 μL of PtNCs (5 pM)
diluted in puriﬁed water were added to a microwell plate followed by
addition of 200 μL of 1-Step Ultra TMB ELSA Substrate Solution
(Thermo Scientiﬁc). The absorbance of the reaction solution at 652
nm was monitored up to 25 min after addition of substrate.
Production of Cysteine-Presenting Nanobody via Site-
Directed Mutagenesis of an Existing Nanobody. The C-terminus
of a validated nanobody against p24, 59H10, characterized in Gray et
al., comprises an alanine spacer, myc and His6 tags.
30 To insert a Cys
residue in this region to generate ···HHHHHHCZ the following
primers were used with the QuikChange Site-Directed Mutagenesis kit
(Agilent) following the manufacturer’s instructions, veriﬁed by






Mutations were veriﬁed by sequencing.
Site-Selective Modiﬁcation of Nanobody. Site-selective mod-
iﬁcation of the cysteine presenting nanobody was achieved through
reaction of the reduced nanobody with bromopyridazinedione-PEG8-
biotin. Synthesis and characterization (NMR, IR, LRMS, HRMS) of
pyridazinedione−biotin, and subsequent site-selective modiﬁcation of
the cysteine-mutated nanobody (shown by LCMS, SDS-PAGE) is
described in the Supporting Information.
Characterization of Antibody Components. Aﬃnity constants
for antibody components were measured on Octet RED96 instrument
(Pall ForteBio LLC, as previously described in Gray et al.).30
Preparation of PtNC-Ampliﬁed Lateral Flow Immunoassay.
The lateral ﬂow strips with polystreptavidin test line were
manufactured by Mologic Ltd. (UK) (Batch Number ML-ICL-
130317). The strips were 33 mm long and 5 mm wide. The distance
between the test line and the bottom of the strip was 7 mm. Clinical
utility of assay was tested on human plasma from HIV Seroconversion
Panel Donor No. 75062 (ZeptoMetrix Corp., product code:
HIV9079). Donor source plasma was collected from a U.S. licensed
blood collection facility. Donor was untreated and asymptomatic
throughout the collection period. A 50 μL portion of each panel
sample was run on PtNC LFIA (outlined below).
All PtNC lateral ﬂow assays for p24 detection were performed by
submerging a polystreptavidin strip into a 96-well plate containing the
following solution in each well: 10 μL of nanobody−biotin (200 nM),
50 μL p24 spiked into: FBS; plasma; or infected patient clinical plasma
sample; and 15 μL PtNC antibody conjugate (300 pM). When the
solution had fully wicked up the strip (ca. 10 min), the strip was
moved into another well ﬁlled with 100 μL of assay running buﬀer for
3 min to wash through any residual serum (which may contain
peroxidases that can also perform catalysis). Next, the strip was
immersed in another well for 5 min ﬁlled with 330 μL (enough
solution to cover test line on strip in well) freshly prepared PtNC
development solution containing a modiﬁed Pierce CN/DAB (4-
chloro-1-naphthol/3,3′-diaminobenzidine, tetrahydrochloride) Sub-
strate Kit (Thermo Scientiﬁc) adjusted with hydrogen peroxide
solution 30% (w/w) (Sigma) to a ﬁnal added peroxide concentration
of 4 M. Finally, the strip was moved into a well containing 330 μL
puriﬁed water for 1 min to stop the reaction. Strips were imaged with
an iPhone 6 mobile phone camera for all experiments, except the
clinical samples, which were imaged using a camera (Canon
PowerShot G15) approved for use in contained environment for
handling infectious samples. Images of strips were acquired 5 min after
removal from the water.
Preparation of Aged Samples for Accelerated Stability
Testing. An accelerated aging test was carried out to simulate real-
time shelf life aging. All aging experiments were performed in a
nonbinding 96-well plate (Corning, UK). In each well, 15 μL of either
PtNC−antibody conjugate (300 pM) or HRP−antibody conjugate (50
nM) in particle storage buﬀer was added, followed by 10 μL
nanobody−biotin (200 nM) and 50 μL of particle storage buﬀer.
Plates were immediately frozen at −80 °C for 30 min and freeze-dried
overnight. When removed from the freeze-dryer, plates were stored in
a sealed plastic bag ﬁlled with silica bead desiccant at either room
temperature or 44 °C for accelerated aging study. Aging at 44 °C for
ca. 42 days is functionally equivalent to room temperature (23 °C)
aging for 6 months. Aging conditions were selected following
guidelines of ASTM F1980 Standard Guide for Accelerated Aging of
Sterile Medical Device Packages and Westpak Accelerated Aging Time
Calculator.43,44 Accelerated aging techniques are based on the
assumption that the chemical reaction involved in the deterioration
of materials follow the Arrhenius reaction rate function, which states
that a 10 °C increase in temperature will cause the reaction rate to
double.
To examine long-term stability of reagents, 50 μL spiked serum or
plasma was added to freeze-dried reagents. After dissolution of
reagents in sample, strip was inserted into the well following above
protocol for wash and development.
Structural Model of Nanobody. The structural model was
predicted using the i-tasser Web server, http://zhanglab.ccmb.med.
umich.edu/I-TASSER/, for the sequence provided.45
Image Analysis. Images of lateral ﬂow strips were acquired using
an Apple iPhone 6 and analyzed with ImageJ software.46 ImageJ Gel
Analyzer plug-in was used to plot intensity proﬁles of LFIA strips and
analyze test line intensities (Supplementary Figure 11).
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